Angioplasty Summit 2004 > Syllabus

Welcome
Course Director
Hot Topic
Invited Faculty
Meeting at a
Glance
Program
Abstracts
Poster Abstracts -
Guideline -
Syllabus
Factoid
Expert Lectures
Gallery 2004
Hotel
Accommodations
Exhibition
Sights of Korea
Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction.
Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study.
Relation of inflammation and benefit of statins after percutaneous coronary interventions.
Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction.
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction.
Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease.
Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women.
Beta-blockers reduce the incidence of clinical restenosis: prospective study of 4840 patients undergoing percutaneous coronary revascularization.
Effects of amlodipine on ischemia after percutaneous transluminal coronary angioplasty: secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) Study.
Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation.
Effects of glucose-insulin-potassium infusion on chronic ischaemic left ventricular dysfunction.
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease.
Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.
Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).
Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
Effect of angiotensin-converting enzyme inhibition on restenosis after coronary stenting.
Endothelin receptor blockers in cardiovascular disease.
Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation.
Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study.
Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial.
Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker.
Nicorandil versus isosorbide dinitrate as adjunctive treatment to direct balloon angioplasty in acute myocardial infarction.